5 new endocrine therapy adherence trajectories for HR+ breast cancer

  • Breast Cancer Res Treat

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The French VICAN2 cohort study finds 5 unique trajectories for adherence to adjuvant endocrine therapy (AET) in patients with nonmetastatic, hormone receptor (HR)-positive breast cancer.
  • Not receiving chemotherapy and lacking a personalized care plan are associated with the 2 worst trajectories.

Why this matters

  • Clinicians have a new way to categorize adherence to AET and identify risk and protective factors.

Study design

  • Retrospective cohort study of women (n=674) from initiation to cessation of the 5-year period for AET for HR+ breast cancer, using an administrative database.
  • Trajectories were identified by group-based trajectory modeling.
  • Funding: French National Institute of Cancer; others.

Key results

  • Newly identified adherence trajectories and their prevalence:
    • Quick decline and stop (by end of 2nd year): 5.2%.
    • Moderate decline and stop (by end of 4th year): 6.4%.
    • Slow decline: 17.2%.
    • High adherence (AET taken >80% to 95% of the time): 30.0%.
    • Maintenance of very high adherence (AET taken >95% of the time): 41.2%.
  • Risk factors for fitting into the worst 2 adherence categories:
    • Did not receive chemotherapy (vs received chemotherapy): adjusted OR (aOR), 2.07 (95% CI, 1.19-3.63); and
    • Lack of a personalized care plan (vs have a care plan): aOR, 1.69 (95% CI, 1.01-2.83).

Limitations

  • Observational design.